Momenta Pharmaceuticals, Inc.

Momenta Pharmaceuticals, Inc.

Momenta Pharmaceuticals was founded in 2001 and is based in Cambridge, Massachusetts. Momenta Pharmaceuticals, Inc., a biotechnology company, specializes in the structural analysis of complex mixture drugs. The company applies its technology for the development of generic versions of complex drug products, as well as for the discovery and development of novel drugs. Its product candidates include M-Enoxaparin, a generic version of Lovenox that is used to prevent and treat deep vein thrombosis, and to support the treatment of acute coronary syndromes; M356, a technology-enabled generic version of Copaxone, which is used for the reduction of the frequency of relapses in patients with relapse-remitting multiple sclerosis; and M118, an anticoagulant. The company also involves in developing generic or biosimilar glycoprotein products. Momenta Pharmaceuticals has collaborations with Sandoz AG and Sandoz Inc. to develop and commercialize injectable enoxaparin. The company was formerly known as Mimeon, Inc. and changed its name to Momenta Pharmaceuticals, Inc. in September 2002.

Contact Details

Office Address

Momenta Pharmaceuticals, Inc.
675 West Kendall Street
Cambridge, MA, USA 02142
Phone: (617) 491-9700
Fax: (617) 621-0431

Executives

Chief Exec. Officer

Mr. Craig A. Wheeler

Co-Founder & Chief Scientific Officer

Dr. Ganesh Venkataraman

Business Reviews for Momenta Pharmaceuticals, Inc.

Related Companies